[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Dokmak S, Cabral C, Couvelard A, Aussilhou B, Belghiti J, Sauvanet A: Pancreatic metastasis from nephroblastoma: an unusual entity. JOP; 2009;10(4):396-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis from nephroblastoma: an unusual entity.
  • CONTEXT: Pancreatic metastasis from renal cell carcinoma is a well-known entity.
  • When metastatic disease is limited to the pancreas, pancreatic resection is the optimal treatment.
  • Pancreatic metastases from a nephroblastoma are very rare.
  • CASE REPORT: We report an extremely rare case of pancreatic metastases in a 20-year-old man who had a right nephroblastoma resected at 9 years of age and liver metastases treated by right hepatectomy at 18 years of age.
  • Pancreatic metastasis was revealed by acute pancreatitis.
  • Imaging studies revealed one 2 cm nodule in the pancreatic head with upstream dilatation of the Wirsung duct.
  • Imaging studies revealed no other localization except a 1.5 cm liver nodule.
  • Surgical resection was performed without preoperative chemotherapy because the patient was symptomatic and had already received numerous chemotherapy protocols.
  • Pathological examination confirmed pancreatic and liver metastases from a nephroblastoma composed of blastematous cells mixed with embryonic tubular structures without lymph node metastases.
  • After resection, the patient received adjuvant high dose chemotherapy with autologous hematopoietic stem-cell support.
  • After a 21-month follow-up, the patient was in good general condition but had liver recurrence without intra-pancreatic recurrence.
  • CONCLUSION: This is probably the first case of pancreatic metastasis from a nephroblastoma reported in a living patient.
  • A nephroblastoma, like clear cell renal carcinoma, can be considered a possible etiology of pancreatic metastasis from a primary renal tumor.
  • [MeSH-major] Kidney Neoplasms / pathology. Pancreatic Neoplasms / secondary. Wilms Tumor / pathology
  • [MeSH-minor] Combined Modality Therapy. Drug Therapy / methods. Humans. Male. Pancreaticoduodenectomy / methods. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581742.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


2. Koizumi M, Sata N, Kasahara N, Morishima K, Sasanuma H, Sakuma Y, Shimizu A, Hyodo M, Yasuda Y: Remnant pancreatectomy for recurrent or metachronous pancreatic carcinoma detected by FDG-PET: two case reports. JOP; 2010;11(1):36-40
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remnant pancreatectomy for recurrent or metachronous pancreatic carcinoma detected by FDG-PET: two case reports.
  • CONTEXT: Although surgical resection is the only curative therapeutic option for recurrent or metachronous pancreatic carcinomas, most such cancers are beyond surgical curability.
  • We herein report on two rare cases of remnant pancreatectomy used to treat recurrent or metachronous pancreatic carcinomas.
  • CASE REPORTS: CASE#1 A 65-year-old male developed weight loss and diabetes mellitus 83 months after a pylorus-preserving pancreaticoduodenectomy followed by two years of adjuvant chemotherapy (5-fluorouracil plus leucovorin plus mitomycin C) for a pancreatic carcinoma in the head of the pancreas (stage IA).
  • An abdominal CT scan revealed a 3 cm tumor in the remnant pancreas which appeared as a 'hot' nodule on FDG-PET.
  • A remnant distal pancreatectomy was performed and a pancreatic carcinoma similar in profile to the primary lesion (stage IIB) was confirmed pathologically.
  • CASE#2 A 67-year-old male showed increased CA 19-9 levels 25 months after a distal pancreatectomy for a pancreatic carcinoma in the body of the pancreas (stage IA).
  • An abdominal CT scan revealed a cystic lesion in the cut end of the pancreas which appeared as a 'hot' nodule on FDG-PET.
  • A remnant proximal pancreatectomy with duodenectomy was performed and a metachronous pancreatic carcinoma (stage III) was confirmed pathologically.
  • CONCLUSION: Remnant pancreatectomy can be considered a treatment option for recurrent or metachronous pancreatic carcinomas.
  • FDG-PET can play a key role in detecting remnant pancreatic carcinomas.
  • [MeSH-major] Carcinoma / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065550.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


3. Bauer C, Bauernfeind F, Sterzik A, Orban M, Schnurr M, Lehr HA, Endres S, Eigler A, Dauer M: Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut; 2007 Sep;56(9):1275-82
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
  • Combination with other treatment modalities such as chemotherapy may overcome immunoresistance of cancer cells.
  • It has been shown previously that gemcitabine sensitises human pancreatic carcinoma cells against CTL-mediated lysis.
  • Here, a murine pancreatic carcinoma model was used to investigate whether combination with gemcitabine increases therapeutic efficacy of DC-based vaccination.
  • For prophylactic vaccination, mice were vaccinated three times at weekly intervals prior to tumour challenge with Panc02 cells.
  • Therapeutic vaccination was started when tumours formed a palpable nodule.
  • In the subcutaneous tumour model, therapeutic DC-based vaccination was equally effective as gemcitabine (14% vs 17% survival at day 58 after tumour challenge; controls, 0%).
  • CONCLUSION: DC-based immunotherapy may not only be successfully combined with gemcitabine for the treatment of advanced pancreatic carcinoma, but may also be effective in preventing local recurrence or metastatisation in tumour-free patients.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Dendritic Cells / immunology. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / prevention & control. Vaccination / methods
  • [MeSH-minor] Animals. Cell Line, Tumor. Combined Modality Therapy / methods. Disease Models, Animal. Immunologic Memory / immunology. Injections, Intraperitoneal. Injections, Subcutaneous. Lung Neoplasms / secondary. Mice. Mice, Inbred C57BL. Survival Analysis. T-Lymphocytes, Cytotoxic / immunology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Immunization.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunother. 2005 Jul-Aug;28(4):332-42 [16000951.001]
  • [Cites] J Immunol. 2003 May 15;170(10):4905-13 [12734333.001]
  • [Cites] J Immunother. 2005 Sep-Oct;28(5):505-16 [16113607.001]
  • [Cites] Oncology. 2005;69(1):81-7 [16088235.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7580-4 [16140921.001]
  • [Cites] Semin Oncol. 2005 Aug;32(4 Suppl 6):S1-3 [16143160.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):10079-87 [16267034.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):59-65 [16330943.001]
  • [Cites] J Immunother. 2000 Mar-Apr;23(2):177-83 [10746543.001]
  • [Cites] Annu Rev Immunol. 2000;18:767-811 [10837075.001]
  • [Cites] J Immunol. 2000 Sep 15;165(6):3492-6 [10975870.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2038-46 [11280764.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):925s-932s [11300493.001]
  • [Cites] J Immunol. 2001 Jun 15;166(12):7370-80 [11390488.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6445-50 [11522639.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6451-8 [11522640.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2347-52 [11956095.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2353-8 [11956096.001]
  • [Cites] Cancer Lett. 2002 Oct 8;184(1):37-47 [12104046.001]
  • [Cites] Eur J Immunol. 2002 Nov;32(11):3235-45 [12555669.001]
  • [Cites] Int J Oncol. 2003 Mar;22(3):651-6 [12579320.001]
  • [Cites] Am J Surg. 2003 May;185(5):476-80 [12727570.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4490-6 [12907622.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8962-7 [14695214.001]
  • [Cites] J Immunol. 2004 Jan 15;172(2):1304-10 [14707109.001]
  • [Cites] Pancreas. 2004 Jan;28(1):e26-31 [14707745.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3668-78 [15150127.001]
  • [Cites] J Clin Immunol. 2004 Jul;24(4):462-70 [15163903.001]
  • [Cites] Cancer Lett. 2004 Nov 25;215(2):179-86 [15488636.001]
  • [Cites] Cancer Res. 1984 Feb;44(2):717-26 [6692374.001]
  • [Cites] Eur J Immunol. 1991 Nov;21(11):2891-4 [1718764.001]
  • [Cites] Cell. 1994 Jan 14;76(1):17-27 [8287475.001]
  • [Cites] Curr Opin Immunol. 1994 Apr;6(2):273-8 [8011210.001]
  • [Cites] J Exp Med. 1995 Aug 1;182(2):389-400 [7629501.001]
  • [Cites] Eur J Immunol. 1996 Mar;26(3):659-68 [8605935.001]
  • [Cites] J Exp Med. 1997 Feb 3;185(3):453-9 [9053445.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Nat Med. 1998 Mar;4(3):328-32 [9500607.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):847-62 [15829493.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3509-16 [15908661.001]
  • [Cites] Cancer Immunol Immunother. 2005 Sep;54(9):915-25 [15782312.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):8950-8 [16061910.001]
  • [Cites] Immunol Lett. 2006 Mar 15;103(2):142-8 [16313973.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):759-64 [16369992.001]
  • [Cites] J Immunol. 2005 Jul 15;175(2):820-8 [16002679.001]
  • (PMID = 17395611.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Other-IDs] NLM/ PMC1954993
  •  go-up   go-down


Advertisement
4. Crescentini F, Deutsch F, Sobrado CW, Araújo Sd: Umbilical mass as the sole presenting symptom of pancreatic cancer: a case report. Rev Hosp Clin Fac Med Sao Paulo; 2004 Aug;59(4):198-202
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Umbilical mass as the sole presenting symptom of pancreatic cancer: a case report.
  • A 64-year-old woman, previously healthy, presented vague abdominal discomfort and a hard umbilical nodule for 1 week, which was first diagnosed as an incarcerated umbilical hernia.
  • After immunohistochemical analysis and computerized tomography, she was diagnosed with pancreatic cancer.
  • She received palliative chemotherapy.
  • Clinical suspicion should lead to a careful additional evaluation whenever an umbilical nodule presents with malignant signs.
  • [MeSH-major] Adenocarcinoma / secondary. Pancreatic Neoplasms / pathology. Umbilicus
  • [MeSH-minor] Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15361985.001).
  • [ISSN] 0041-8781
  • [Journal-full-title] Revista do Hospital das Clínicas
  • [ISO-abbreviation] Rev Hosp Clin Fac Med Sao Paulo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


5. Mizuta Y, Akazawa Y, Shiozawa K, Ohara H, Ohba K, Ohnita K, Isomoto H, Takeshima F, Omagari K, Tanaka K, Yasutake T, Nakagoe T, Shirono K, Kohno S: Pseudomyxoma peritonei accompanied by intraductal papillary mucinous neoplasm of the pancreas. Pancreatology; 2005;5(4-5):470-4
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdominal computed tomography revealed massive ascites, thickened peritoneum, and a cystic lesion of the pancreas.
  • Endoscopic retrograde pancreatography revealed a cystic lesion with the defect probably due to mural nodule and mucin, communicating with the pancreatic duct.
  • The patient received intraperitoneal perfusion of saline heated to 42 degrees C containing cisplatin, etoposide, and mitomycin C, followed by 24 courses of postoperative chemotherapy with gemcitabine.
  • The patient remains in good general condition with no signs of progression of PMP for 2 years, but with a gradual and progressive enlargement of the pancreatic cystic lesion.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / pathology. Chemotherapy, Cancer, Regional Perfusion. Cisplatin / administration & dosage. Deoxycytidine / analogs & derivatives. Etoposide / administration & dosage. Humans. Hyperthermia, Induced. Infusions, Parenteral. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel and IAP.
  • (PMID = 15983445.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 19
  •  go-up   go-down


6. Mattavelli F, Collini P, Pizzi N, Nicolai N, Pennacchioli E, Thyroid Study Group: Thyroid as a target of metastases: a case of metastatic seminoma in a patient who died of a second cancer. Tumori; 2009 Jan-Feb;95(1):91-3
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The thyroid is a rare site of metastases from any cancer, but any patient with a previous oncologic disease should inquire about a thyroid nodule.
  • Perhaps the patient could have been treated with chemotherapy alone, as he developed a second cancer 6 years after the diagnosis, and that event could have been related to delivered therapies, mainly radiotherapy.
  • CONCLUSION: This type of seminoma spread has previously been described only once, and it is not a typical route for metastasis by seminoma.
  • In view of this unusual finding, we reinforce the need for accurate diagnostic planning of any thyroid nodule occurring in a patient with a previous cancer history.
  • Accurate staging is crucial in planning the treatment and follow-up of seminoma.
  • Currently, greater attention is due to management of the disease at diagnosis, as emerging data support a risk of a second cancer among patients treated with radiotherapy and chemotherapy for a testicular cancer.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Fatal Outcome. Humans. Lymphatic Metastasis / pathology. Male. Orchiectomy. Pancreatic Neoplasms / secondary. Radiotherapy. Thyroidectomy


7. Borgonovo G, Razzetta F, Assalino M, Varaldo E, Puglisi M, Ceppa P: Rectal hepatoid carcinoma with liver metastases in a patient affected by ulcerative colitis. Hepatobiliary Pancreat Dis Int; 2008 Oct;7(5):539-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient underwent left hepatectomy and alcoholisation of a small deep nodule in segment 8.
  • The patient was well during the first 6 months and refused any adjuvant chemotherapy.
  • The prognosis is poor despite an aggressive and multimodal therapeutic strategy.
  • [MeSH-minor] Adult. Biopsy. Chemoembolization, Therapeutic. Diagnostic Errors. Fatal Outcome. Hepatectomy. Humans. Immunohistochemistry. Male. Neoplasm Staging. Proctocolectomy, Restorative. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18842504.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Yamashita S, Sakon M, Hiura Y, Nakano K, Higaki N, Murakami M, Hayashida H, Kan K, Ichihara T: [A case of metastases of umbilicus (Sister Mary Joseph's nodule)]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2112-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastases of umbilicus (Sister Mary Joseph's nodule)].
  • We report a case of advanced unresectable pancreatic cancer (cT4N1M0/stage IVa).
  • Chemo-radiation therapy (CRT) with GEM (1,000 mg/body) was administered once a week on days 1, 8 and 15 for 3 weeks.
  • The radiotherapy dose was 45 Gy (1.5 Gy x 2/day, 15 days).
  • After CRT, the patient was treated with a GEM+ UFT-E combination chemotherapy.
  • When that was done, CT scan revealed metastases of umbilicus (Sister Mary Joseph's nodule) and the liver.
  • Microwave Coagulation Therapy for the liver metastasis and tumorectomy for metastasis of umbilicus were performed.
  • But he died after 4 months from the therapies.
  • [MeSH-major] Abdominal Neoplasms / secondary. Pancreatic Neoplasms / pathology. Umbilicus / pathology
  • [MeSH-minor] Aged. Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Fatal Outcome. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Male. Tomography, X-Ray Computed. Treatment Failure

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106540.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DU-PAN-2 antigen, human
  •  go-up   go-down


9. Sugimoto K, Okada K, Nakahira S, Okamura S, Miki H, Nakata K, Suzuki R, Yoshimura M, Uji K, Yoshida A, Tamura S: [A case of metastatic pancreatic cancer after combination chemotherapy with uracil-tegafur and gemcitabine]. Gan To Kagaku Ryoho; 2009 Feb;36(2):321-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic pancreatic cancer after combination chemotherapy with uracil-tegafur and gemcitabine].
  • We report a case of pancreas head cancer with liver metastasis treated with uracil-tegafur (UFT) and gemcitabine combined chemotherapy.
  • We planned to perform a pancreatoduodenectomy, but a small nodule was found at laparotomy on the liver surface.
  • We performed 9 courses of UFT and gemcitabine (GEM) combination chemotherapy.
  • After treatment with an additional 11 courses of chemotherapy, he took S-1 orally because of a tumor recurrence.
  • Combination chemotherapy and surgery enhanced the survival benefit in this case.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Tegafur / therapeutic use. Uracil / therapeutic use
  • [MeSH-minor] Aged. Combined Modality Therapy. Fatal Outcome. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223756.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


10. Hajri A, Wack S, Lehn P, Vigneron JP, Lehn JM, Marescaux J, Aprahamian M: Combined suicide gene therapy for pancreatic peritoneal carcinomatosis using BGTC liposomes. Cancer Gene Ther; 2004 Jan;11(1):16-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined suicide gene therapy for pancreatic peritoneal carcinomatosis using BGTC liposomes.
  • Peritoneal dissemination is a common end-stage complication of pancreatic cancer for which novel therapeutic modalities are actively investigated, as there is no current effective therapy.
  • Thus, we evaluated, in a mouse model of pancreatic peritoneal carcinomatosis, the therapeutic potential of a novel nonviral gene therapy approach consisting of bis-guanidinium-tren-cholesterol (BGTC)-mediated lipofection of a combined suicide gene system.
  • Human BxPC-3 pancreatic cells secreting the carcinoembryonic antigen (CEA) tumor marker were injected into the peritoneal cavity of nude mice.
  • Administration of the lipoplexes was followed by treatment with the corresponding prodrugs ganciclovir and 5-fluorocytosine.
  • Indeed, HSV-TK mRNA was detected in tumor nodule tissues by semiquantitative reverse transcription-polymerase chain reaction analysis.
  • These expression analyses also showed that transgene expression lasted for about 2 weeks and was preferential for the tumor nodules, this tumor preference being in good agreement with the absence of obvious treatment-related toxicity.
  • Most importantly, mice receiving the full treatment scheme (BGTC liposomes, suicide genes and prodrugs) had significantly lower serum CEA levels than those of the various control groups, a finding indicating that peritoneal carcinomatosis progression was strongly reduced in these mice.
  • In conclusion, our results demonstrate the therapeutic efficiency of BGTC-mediated i.p. lipofection of a combined suicide gene system in a mouse peritoneal carcinomatosis model and suggest that BGTC-based prodrug-activating gene therapy approaches may constitute a potential treatment modality for patients with peritoneal carcinomatosis and minimal residual disease.
  • [MeSH-major] Cholesterol / analogs & derivatives. Genes, Transgenic, Suicide / genetics. Genetic Therapy / methods. Guanidines. Liposomes / administration & dosage. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Animals. Biopsy. Carcinoembryonic Antigen / analysis. Cell Division / drug effects. Cell Line, Tumor. Cytosine Deaminase / genetics. Cytosine Deaminase / metabolism. Disease Progression. Escherichia coli. Female. Flucytosine / pharmacology. Flucytosine / therapeutic use. Ganciclovir / pharmacology. Ganciclovir / therapeutic use. Humans. Mice. Mice, Nude. Peritoneal Cavity / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Simplexvirus / enzymology. Simplexvirus / genetics. Thymidine Kinase / genetics. Thymidine Kinase / metabolism. Transfection

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUCYTOSINE .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14681723.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3-(N(4)-(N(1),N(8)-diguanidinospermidine)carbamoyl)cholesterol; 0 / Carcinoembryonic Antigen; 0 / Guanidines; 0 / Liposomes; 0 / RNA, Messenger; 97C5T2UQ7J / Cholesterol; D83282DT06 / Flucytosine; EC 2.7.1.21 / Thymidine Kinase; EC 3.5.4.1 / Cytosine Deaminase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


11. Masaki T, Ohkawa S, Hirokawa S, Miyakawa K, Tamai S, Tarao K: [A case of advanced pancreatic cancer showing remarkable response to gemcitabine treatment]. Gan To Kagaku Ryoho; 2003 Sep;30(9):1333-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced pancreatic cancer showing remarkable response to gemcitabine treatment].
  • A 46-year-old woman with a 3-month history of upper abdominal pain was referred to our hospital because of the presence of a pancreatic mass and multiple hepatic nodules on abdominal ultrasonography (US) and computed tomography (CT).
  • We concluded that the patient had pancreatic cancer with multiple hepatic metastases on the findings of endoscopic retrograde cholangiopancreatography (ERCP) and fine needle aspiration biopsy of the hepatic nodule.
  • The patient received gemcitabine treatment.
  • Gemcitabine 1,000 mg/m2 was administered once a week for 3 weeks followed by a week of rest, this constituting 1 cycle of treatment.
  • Partial responses (PR) of both pancreatic and hepatic lesions were observed after the first cycle of the gemcitabine treatment, and serum concentrations of CEA and CA19-9 remarkably decreased.
  • Such effectiveness of the gemcitabine treatment lasted for the following 4 cycles.
  • In general, chemotherapy has few effects on an advanced pancreatic cancer.
  • We report a case of advanced pancreatic cancer that could obtain remarkable antineoplastic effect and clinical benefit with gemcitabine treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Drug Administration Schedule. Humans. Karnofsky Performance Status. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14518416.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


12. Gardner-Thorpe J, Ito H, Ashley SW, Whang EE: Autoantibody-mediated inhibition of pancreatic cancer cell growth in an athymic (nude) mouse model. Pancreas; 2003 Aug;27(2):180-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoantibody-mediated inhibition of pancreatic cancer cell growth in an athymic (nude) mouse model.
  • AIM: To assess whether antiribosomal P autoantibodies could be useful as a novel form of immunotherapy for pancreatic cancer.
  • METHODOLOGY: Three pancreatic cancer cell lines were incubated with antiribosomal P or normal human immunoglobulin.
  • Tumor nodule size was measured weekly.
  • RESULTS: Antiribosomal P antibody inhibited pancreatic cancer cell proliferation up to 54.6% (p < 0.01) and was associated with a threefold increase in the rate of apoptosis (p < 0.05).
  • Tumor volume after 4 weeks of treatment was 23.2 mm3, versus 141.5 mm3 for the control group (p < 0.05).
  • CONCLUSION: Antiribosomal P autoantibody at levels similar to those that can exist in SLE inhibits the growth of pancreatic cancer cells, in vitro and in vivo.
  • [MeSH-major] Autoantibodies / pharmacology. Pancreatic Neoplasms / drug therapy. Protozoan Proteins. Xenograft Model Antitumor Assays / methods
  • [MeSH-minor] Animals. Antibody Specificity. Apoptosis / drug effects. Binding, Competitive. Cell Division / drug effects. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Cell Survival / drug effects. Dose-Response Relationship, Drug. Humans. In Situ Nick-End Labeling. Male. Mice. Mice, Nude. Neoplasm Transplantation. Ribosomal Proteins / immunology. Time Factors

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12883268.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / L12E protein, Trypanosoma cruzi; 0 / Protozoan Proteins; 0 / Ribosomal Proteins
  •  go-up   go-down


13. Niinobu T, Nakagawa S, Itani Y, Nishikawa Y, Amano M, Higaki N, Hayashida H, Sakon M: [Rectal stenosis due to Schnitzler metastasis following surgery for gastric cancer--a case successfully treated with TS-1 and CDDP combination chemotherapy]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1761-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rectal stenosis due to Schnitzler metastasis following surgery for gastric cancer--a case successfully treated with TS-1 and CDDP combination chemotherapy].
  • The patient, a 40-year-old woman, underwent total gastrectomy and excision of the pancreatic tail, spleen and gallbladder for gastric cancer in September 2000.
  • The lesion was judged to be P1, SE, H0, N2 and Stage IV and the patient was managed on a regular schedule as an outpatient.
  • In September 2004, she passed blood-stained feces and rectal palpation detected a hard nodule at the anterior rectal wall.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Diseases / drug therapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / secondary. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cholecystectomy. Cisplatin / administration & dosage. Constriction, Pathologic. Drug Combinations. Female. Gastrectomy. Humans. Oxonic Acid / administration & dosage. Pancreatectomy. Pyridines / administration & dosage. Splenectomy. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315933.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Nakao A, Takeda S, Shimoyama S, Kasuya H, Kimata H, Teshigahara O, Sawaki M, Kikumori T, Kodera Y, Nagasaka T, Goshima F, Nishiyama Y, Imai T: Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer. Curr Cancer Drug Targets; 2007 Mar;7(2):169-74
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.
  • We have evaluated the safety and effect of HF10 against recurrent breast cancer since 2003 and also applied HF10 to non-resectable pancreatic cancer since 2005.
  • An oncolytic herpes simplex virus type 1, mutant HF10, has been isolated and evaluated for anti-tumor efficacy in syngeneic immunocompetent mouse models.
  • From long time before clinical trial, we have found that the mutant virus can have remarkable potential to effectively treat cancer in experimental studies using animals, and that all of the surviving mice acquire resistance to rechallenge of the tumor cells.
  • For each patient, 0.5 ml HF10 diluents at various doses were injected into test nodule, and 0.5 ml sterile saline was injected into a second nodule.
  • Also a trial for non-resectable pancreatic cancer being carried out on the basis of the above result has proved to be innocuous and has been in progress to assess the clinical benefit and enhance the potentiality of HF10 against cancer.
  • [MeSH-major] Breast Neoplasms / therapy. Herpesvirus 1, Human / genetics. Mutation. Oncolytic Virotherapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Aged. Animals. Female. Humans. Male. Middle Aged. Research Design. Treatment Outcome. Virus Replication

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17346108.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


15. Romeo S, Milione M, Gatti A, Fallarino M, Corleto V, Morano S, Baroni MG: Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2. Horm Res; 2006;65(3):120-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2.
  • Insulinoma is the most common pancreatic endocrine tumor, accounting for 40% of all pancreatic functional neoplasm, and is characterized by hypersecretion of insulin and hypoglycemia.
  • Elective treatment for insulinomas is surgical enucleation.
  • Medical therapy with diazoxide, followed by somatostatin analogues in some cases, may be necessary to treat the hypoglycemic symptoms.
  • Due to the persistence of hypoglycemia, the patient was started on octreotide LAR treatment, which determined a complete clinical remission with regression of the metastatic lesions in the liver after one year.
  • To our knowledge, the complete regression of the disease in insulinomas treated with long-standing somatostatin analogue therapy has never been reported.
  • Immunohistochemical analysis in tissue specimens showed a strong membrane immunoreactivity for somatostatin receptors type 2 (SSTR2) in both the primary nodule and the metastases.
  • This case underlies the potential impact of the treatment of pancreatic insulinomas with somatostatin analogues, and, if confirmed, the usefulness of SSTR determination in these neoplastic specimens.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Insulinoma / secondary. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Octreotide / therapeutic use. Pancreatic Neoplasms / chemistry. Receptors, Somatostatin / analysis
  • [MeSH-minor] Adult. Apoptosis. Cell Proliferation. Female. Humans. Immunohistochemistry. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 16479142.001).
  • [ISSN] 0301-0163
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; RWM8CCW8GP / Octreotide
  •  go-up   go-down


16. Hayashi T, Ishiwatari H, Ihara H, Kawano Y, Takada K, Miyanishi K, Kobune M, Takimoto R, Sonoda T, Takayama T, Kato J, Niitsu Y: Suppressive effect of sulindac on branch duct-intraductal papillary mucinous neoplasms. J Gastroenterol; 2009;44(9):964-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten of the 22 patients who rejected surgical therapy although their lesions or clinical symptoms met the criteria for surgical resection of the International Association of Pancreatology guidelines were assigned to the treatment group.
  • Branch duct diameter and mural nodule heights were monitored by either magnetic resonance cholangiopancreatography (MRCP) or computed tomography (CT) and by endoscopic ultrasonography (EUS).
  • RESULTS: Both branch duct diameter and mural nodule height of BD-IPMNs in the treatment group were significantly reduced, while those in the control group were unchanged.
  • Immunohistochemical staining for cyclooxygenase-1 and -2 was negative in hyperplasia, adenoma and carcinoma portions of resected pancreatic specimens but was clearly positive for glutathione-S-transferase pi (GST-pi), suggesting that GST-pi is a putative target molecule for sulindac.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Agents / therapeutic use. Pancreatic Neoplasms / drug therapy. Sulindac / therapeutic use
  • [MeSH-minor] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / pathology. Aged. Aged, 80 and over. Anti-Ulcer Agents / therapeutic use. Carcinoma, Pancreatic Ductal / drug therapy. Carcinoma, Pancreatic Ductal / pathology. Cholangiopancreatography, Magnetic Resonance / methods. Drug Delivery Systems. Endosonography / methods. Female. Glutathione S-Transferase pi / drug effects. Glutathione S-Transferase pi / metabolism. Humans. Male. Middle Aged. Omeprazole / therapeutic use. Tomography, X-Ray Computed / methods


17. Kato T, Sato K, Tamahashi N, Yano H, Masuoka HO: [A case of small cell carcinoma of the stomach]. Gan To Kagaku Ryoho; 2005 Oct;32(10):1473-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CPT-11/CDDP chemotherapy achieved a partial response.
  • A 60-year-old man suddenly developed abdominal pain and visited the emergency room.
  • Excisional biopsy was performed to the small liver nodule.
  • Histological findings showed that the liver nodule was metastasis from small cell carcinoma.
  • After operation, one course of FP chemotherapy was performed, but the liver metastasis increased in size.
  • Then we changed to CPT-11/CDDP chemotherapy as second-line therapy, and achieved partial remission (PR) of both the liver metastasis and gastric tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Gastrectomy. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Invasiveness. Pancreatic Neoplasms / pathology. Rupture, Spontaneous. Stomach Rupture / etiology

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227752.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


18. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG: Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab; 2009 Feb;94(2):386-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EVIDENCE ACQUISITION: We present a patient with von Hippel-Lindau disease with multiple renal and pancreatic tumors and a malignant pheochromocytoma infiltrative of the sacrum and associated with lymph nodule metastases.
  • EVIDENCE SYNTHESIS: Treatment against malignant pheochromocytoma with surgery, chemotherapy, or participation in clinical trials was not feasible because of the patient's poor performance status, the presence of multiple tumors, and the extension of the pheochromocytoma into the bones.
  • Six months of treatment with sunitinib was associated with normalization of the patient's performance status and blood pressure, absence of symptoms of catecholamine excess, weight gain, disappearance of pain, shrinkage of each of the tumors (50% in the largest renal tumor, 38% in the largest islet cell tumor, 21% in the pelvic malignant pheochromocytoma), and reduction of plasma normetanephrines and chromogranin A.
  • CONCLUSION: This study provides evidence that targeting tyrosine kinase receptors such as the vascular endothelial growth factor pathway and the platelet-derived growth factor-beta receptor may have value in the treatment of VHL-related tumors including pheochromocytoma.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Indoles / therapeutic use. Neoplasms, Multiple Primary / drug therapy. Pheochromocytoma / drug therapy. Pyrroles / therapeutic use. von Hippel-Lindau Disease / drug therapy
  • [MeSH-minor] Adult. Angiogenesis Inducing Agents / antagonists & inhibitors. Angiogenesis Inhibitors / therapeutic use. Drug Delivery Systems / methods. Female. Humans. Protein Kinase Inhibitors / therapeutic use. Treatment Outcome. Von Hippel-Lindau Tumor Suppressor Protein / genetics

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19017755.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Angiogenesis Inhibitors; 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 0 / sunitinib; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


19. Culafic D, Boricic I, Vojinovic-Culafic V, Zdrnja M: Hepatic tuberculomas. A case report. Rom J Gastroenterol; 2005 Mar;14(1):71-4
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Real-time ultrasonography revealed one hypo-echogenic nodule, 25 mm in size, in the segment II of the liver, and three hypoechogenic nodules, 11-25 mm in diameter, in segments III and IV.
  • Enlarged lymph nodes, 20-50 mm, were observed in the region of the pancreatic head.
  • The tuberculostatic chemotherapy (isoniazid 300 mg/24h; rifampycin 600 mg/24h and pyrazinamid 2000 mg/24h) was applied for 12 months.
  • The patient responded well to the treatment, followed-up for 6-12 months.
  • [MeSH-major] Antitubercular Agents / therapeutic use. Liver Diseases / pathology. Liver Neoplasms / pathology. Tuberculoma / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Humans. Middle Aged. Necrosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800697.001).
  • [ISSN] 1221-4167
  • [Journal-full-title] Romanian journal of gastroenterology
  • [ISO-abbreviation] Rom J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


20. Toivola DM, Ku NO, Resurreccion EZ, Nelson DR, Wright TL, Omary MB: Keratin 8 and 18 hyperphosphorylation is a marker of progression of human liver disease. Hepatology; 2004 Aug;40(2):459-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Keratin hyperphosphorylation correlates with exposure to a variety of stresses in cultured cells and in mouse models of liver, pancreatic, and gallbladder injury, and it is found in association with mouse and human Mallory bodies.
  • We also examined the effect of HCV therapy with interleukin-10 on keratin phosphorylation.
  • In cirrhotic livers, keratin hyperphosphorylation occurred preferentially in hepatic nodule cells adjacent to bridging fibrosis and associated with increased stress kinase activation and apoptosis.
  • Histological and serological improvement after interleukin-10 therapy was accompanied by normalization of keratin hyperphosphorylation on some sites in 7 of 10 patients.
  • [MeSH-minor] Biomarkers / analysis. Case-Control Studies. Disease Progression. Hepatocytes / metabolism. Humans. Interleukin-10 / pharmacology. Keratin-18. Keratin-8. Mutation. Phosphorylation / drug effects

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Association for the Study of Liver Diseases
  • (PMID = 15368451.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK52951; United States / NIDDK NIH HHS / DK / DK56339
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / KRT18 protein, human; 0 / KRT8 protein, human; 0 / Keratin-18; 0 / Keratin-8; 0 / Krt8 protein, mouse; 130068-27-8 / Interleukin-10; 68238-35-7 / Keratins
  •  go-up   go-down






Advertisement